<< [Back to News Releases]

CareFusion statement regarding company-funded clinical study

In response to a recent media story regarding the validity of a CareFusion-funded clinical study, CareFusion issued the following statement:

Jan 30, 2014

Our products are safe and effective. In particular, our skin prep product, ChloraPrep, has been proven effective when used in conjunction with best clinical practices to effectively kill microorganisms prior to surgery or injection. The active agents in ChloraPrep, chlorhexidine gluconate (CHG) in combination with isopropyl alcohol, have been acknowledged for years by multiple independent clinical organizations, including the Centers for Disease Control and Prevention, as a superior agent in prepping skin prior to an invasive procedure. There is a large body of evidence supporting these recommendations that has been published, peer reviewed and recognized by some of the best scientific minds in the world.

A recent news report included the unsubstantiated allegations of a former employee about a CareFusion-funded clinical study published in the New England Journal of Medicine. The government investigated the matter and did not take action on the former employee’s allegations related to the study or its validity. The settlement agreement announced by the government and CareFusion on January 9 did not pertain to the clinical study or its analysis.

As it relates to allegations about CareFusion’s past marketing practices or projects with a health care professional that ended years ago, we chose to settle and resolve the matter to avoid the ongoing cost and distraction. Since the formation of CareFusion in 2009, we have continuously updated and invested in our compliance program to help ensure that today we are adhering to best practices in our industry and the high standards we've set for ourselves.


For further information: Media: Kristen Cardillo, (858) 617-2317, kristen.cardillo@carefusion.com; Investors: Jim Mazzola, (858) 617-1203, jim.mazzola@carefusion.com